Studies on the mechanism for the gastric mucosal protection by famotidine in rats.

The effect of famotidine on gastric lesions induced by the decrease in mucosal defensive resistance was investigated in rats and compared with those of cimetidine, pirenzepine and cetraxate. Famotidine (0.03, 0.1 and 0.3 mg/kg, p.o.) inhibited dose-dependently the development of gastric lesions produced by taurocholate-histamine in doses that suppressed histamine-induced acid secretion in pylorus-ligated rats. The H2-antagonist also prevented gastric mucosal lesions induced by taurocholate-serotonin, iodoacetamide, acidified aspirin and acidified ethanol. Cimetidine, pirenzepine and cetraxate showed the inhibitory effects on almost all types of the gastric lesions, but their inhibitory effects were much less potent than those of famotidine. On the other hand, famotidine inhibited the decreases of gastric mucosal blood flow induced by acidified ethanol and the mucosal contents of glycoprotein induced by water immersion restraint stress. In addition, famotidine increased the transgastric potential difference (PD) and promoted the recovery of decreased transgastric PD induced by acidified ethanol in rats. These results suggest that the preventive effect of famotidine on gastric lesions is attributable not only to suppression of acid secretion but to activation of the gastric mucosal defensive mechanisms.

[1]  D. Graham,et al.  Famotidine, a new H2-receptor antagonist , 1985, Digestive Diseases and Sciences.

[2]  K. Miyata,et al.  Selective and competitive histamine H2-receptor blocking effect of famotidine on the blood pressure response in dogs and the acid secretory response in rats. , 1990, Japanese journal of pharmacology.

[3]  Y. Osada,et al.  Cytoprotective action of cetraxate against HCl.ethanol-induced gastric lesion in rats. , 1988, Japanese journal of pharmacology.

[4]  A. McCullough,et al.  A multicenter, double-blind, randomized, placebo-controlled comparison of nocturnal and twice-a-day famotidine in the treatment of active duodenal ulcer disease. , 1987, Gastroenterology.

[5]  S. Szabó,et al.  Ethanol-induced damage to mucosal capillaries of rat stomach. Ultrastructural features and effects of prostaglandin F2 beta and cysteamine. , 1987, Gastroenterology.

[6]  G. Kajiyama,et al.  Experimental model of gastritis induced by sodium taurocholate in rats. , 1986, Hiroshima journal of medical sciences.

[7]  J. Black,et al.  Further analysis of anomalous pKB values for histamine H2‐receptor antagonists on the mouse isolated stomach assay , 1985, British journal of pharmacology.

[8]  K. Hotta,et al.  [Correlation of quantitative changes of gastric mucosal glycoproteins with ethanol-induced gastric damage in rats]. , 1985, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology.

[9]  G. Porro,et al.  Famotidine (MK-208) in the treatment of gastric ulcer. Results of a multicenter double-blind controlled study. , 1985, Digestion.

[10]  H. Kohei,et al.  Gastric cytoprotection by pirenzepine in rats: evaluating method for cytoprotective activity by antisecretory agents. , 1985, Japanese journal of pharmacology.

[11]  M. Girone,et al.  Inhibition of gastric emptying and secretion by pirenzepine and atropine in rats. , 1984, European journal of pharmacology.

[12]  K. Svanes,et al.  Effect of luminal pH and nutrient bicarbonate concentration on restitution after gastric surface cell injury. , 1983, Surgery.

[13]  T. Takagi,et al.  Kinetics of antisecretory action of a new H2-antagonist, YM-11170, in conscious dogs. , 1983, European journal of pharmacology.

[14]  D. Norris,et al.  Specific binding of 3H-tiotidine to histamine H2 receptors in guinea pig cerebral cortex , 1983, Nature.

[15]  M. Terai,et al.  Effect of a new potent H2-receptor antagonist 3[[[2-[(diaminomethylene)amino]-4-thiazolyl]methyl]thio]-N2- sulfamoylpropionamidine (YM-11170) on gastric mucosal histamine-sensitive adenylate cyclase from guinea pig. , 1983, Biochemical pharmacology.

[16]  B. Hirschowitz,et al.  Effects of pirenzepine and atropine on vagal and cholinergic gastric secretion and gastrin release and on heart rate in the dog. , 1983, The Journal of pharmacology and experimental therapeutics.

[17]  Y. Ishihara,et al.  Effects of antiulcer agents on healing of mepirizole-induced duodenal ulcers in rats. , 1983, Digestion.

[18]  M. Dayton,et al.  Cimetidine-induced bicarbonate production in canine gastric pouches. , 1982, The Journal of surgical research.

[19]  T. Takagi,et al.  Effect of a new potent H2-blocker, 3-]]]2-[(diaminomethylene)amino]-4-thiazolyl]methyl]-thio]-N2-sulfamoylpropionamidine (YM-11170) on gastric secretion induced by histamine and food in conscious dogs. , 1982, Archives internationales de pharmacodynamie et de therapie.

[20]  T. Takagi,et al.  Effect of a new potent H2-blocker, 3-[[[2-(diaminomethylene)amino]-4-thiazolyl]methyl]thio]-N2-sulfamoyl propionamidine (YM-11170), on gastric secretion, ulcer formation and weight of male accessory sex organs in rats. , 1982, Arzneimittel-Forschung.

[21]  S. Szabó,et al.  Sulfhydryl compounds may mediate gastric cytoprotection. , 1981, Science.

[22]  R. Hunt,et al.  Comparison of twice-daily ranitidine with standard cimetidine treatment of duodenal ulcer. , 1981, Gut.

[23]  A. Dembińska-kieć,et al.  Role of prostaglandins in the formation of aspirin-induced gastric ulcers. , 1981, Gastroenterology.

[24]  A. Dembińska-kieć,et al.  Gastric cytoprotection by prostaglandins, ranitidine, and probanthine in rats. Role of endogenous prostaglandins. , 1981, Scandinavian journal of gastroenterology.

[25]  A. Robert.  Cytoprotection by prostaglandins. , 1979, Gastroenterology.

[26]  A. Robert,et al.  Cytoprotection by Prostaglandins in Rats Prevention of Gastric Necrosis Produced by Alcohol, HCl, NaOH, Hypertonic NaCl, and Thermal Injury , 1979 .

[27]  A. Nishida,et al.  Protective effect of cetraxate, a new antiulcer drug, against serotonin-induced ulcer. , 1979, Archives internationales de pharmacodynamie et de therapie.

[28]  W. Schwesinger,et al.  Histamine receptor control of gastric microvasculature in shock. , 1979, The Journal of surgical research.

[29]  M. Guslandi.  Pirenzepine and gastric mucus. , 1979, Scandinavian journal of gastroenterology. Supplement.

[30]  Y. Sudo,et al.  Studies on the mechanism of action of cetraxate [4'-(2-carboxyethyl)phenyl trans-4-aminomethyl cyclohexanecarboxylate hydrochloride], a new anti-ulcer agent. , 1979, Japanese journal of pharmacology.

[31]  P. Guth,et al.  Topical aspirin plus HCl gastric lesions in the rat. Cytoprotective effect of prostaglandin, cimetidine, and probanthine. , 1979, Gastroenterology.

[32]  K. Hirokawa,et al.  Pharmacological and histological studies of gastric mucosal lesion induced by serotonin in rats. , 1978, Archives internationales de pharmacodynamie et de therapie.

[33]  K. Wormsley.  Aspects of duodeno-gastric reflux in man , 1972, Gut.

[34]  K. G. Wormsley.  Aspects ofduodeno-gastric reflux inman , 1972 .

[35]  A. Faur,et al.  [Etiology and pathogenesis of gastric and duodenal ulcer]. , 1970, Medicina interna.

[36]  S. Okabe,et al.  The effects of drugs on the production and recovery processes of the stress ulcer. , 1968, Japanese journal of pharmacology.

[37]  H. Davenport.  Fluid produced by the gastric mucosa during damage by acetic and salicylic acids. , 1966, Gastroenterology.

[38]  J. Black,et al.  The effects of 5‐hydroxytryptamine on gastric secretion in anaesthetized dogs , 1958, The Journal of physiology.

[39]  J. N. Hunt.  Inhibition of gastric emptying and secretion in patients with duodenal ulcer. , 1957, Lancet.

[40]  W. E. Trevelyan,et al.  Studies on yeast metabolism. 1. Fractionation and microdetermination of cell carbohydrates , 1952 .